Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
Total investment incurred for setting up the new R&D Rs 250 crore
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The emergence of new infections in India is a growing concern
Subscribe To Our Newsletter & Stay Updated
